Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.typeArtigo de periódicopt_BR
dc.titleSurvival Of Women With Ovarian Carcinomas And Borderline Tumors Is Not Affected By Estrogen And Progesterone Receptor Status.pt_BR
dc.contributor.authorSallum, Luis Felipept_BR
dc.contributor.authorSarian, Luis Otaviopt_BR
dc.contributor.authorLucci De Angelo Andrade, Lilianapt_BR
dc.contributor.authorVassallo, Josépt_BR
dc.contributor.authorSoares, Fernando Augustopt_BR
dc.contributor.authorPinto, Glauce Aparecidapt_BR
dc.contributor.authorFerreira, Patrícia Andréiapt_BR
dc.contributor.authorDerchain, Sophiept_BR
unicamp.authorLuis Felipe Sallum, Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-UNICAMP, São Paulo, Brazil.pt_BR Otavio Sarian,pt Lucci De Angelo Andrade,pté Vassallo,pt Augusto Soares,pt Aparecida Pinto,ptícia Andréia Ferreira,pt Derchain,pt
dc.subjectBorderline Ovarian Tumorpt_BR
dc.subjectEstrogen Receptorpt_BR
dc.subjectOvarian Carcinomapt_BR
dc.subjectProgesterone Receptorpt_BR
dc.subjectTissue Microarraypt_BR
dc.description.abstractTo examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.en
dc.relation.ispartofJournal Of Gynecologic Oncologypt_BR
dc.relation.ispartofabbreviationJ Gynecol Oncolpt_BR
dc.identifier.citationJournal Of Gynecologic Oncology. v. 24, n. 2, p. 167-76, 2013-Apr.pt_BR
dc.description.provenanceMade available in DSpace on 2015-11-27T13:31:42Z (GMT). No. of bitstreams: 1 pmed_23653835.pdf: 1713362 bytes, checksum: 223e06465854e164572889998b9070c1 (MD5) Previous issue date: 2013en
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_23653835.pdf1.67 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.